Unknown

Dataset Information

Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience.


ABSTRACT: Nimotuzumab is a humanized anti-EGFR IgG1 monoclonal antibody and demonstrates a better safety profile than other anti-EGFR antibodies due to its intermediate affinity. Since it was approved in China for the treatment of nasopharyngeal cancer (NPC), it has been widely used in NPC and in many clinical trials for other cancer types. However, the optimal dose and administration frequency of nimotuzumab that should be used and which kind of cancer patients will be more benefited from nimotuzumab is still unknown. In this retrospective study, 205 advanced cancer patients with colorectal cancer, esophageal cancer, head and neck cancer, gastric cancer, non-small cell lung cancer, or other cancers from mainland China, treated with nimotuzumab in combination with chemotherapy, were enrolled. Over 6

SUBMITTER: Xu S 

PROVIDER: S-EPMC5078104 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature